Riskpilot← Back to searchSign inGet full accessGALECTO BIOTECH ApS
APSActiveCVR 34878366Ole Maaløes Vej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20121 employees
Revenue 2024
DKK 5,5M
-64% vs 2023
EBITDA margin
5.6%
-87% vs 2023
Equity ratio
95.9%
Financial strength
Net profit 2024
DKK 310K
-63% vs 2023
| Revenue | DKK 5,5M | -64% |
| EBITDA | DKK 309K | -87% |
| Net profit | DKK 310K | -63% |
| Total assets | DKK 8,9M | -16% |
| Equity | DKK 8,6M | +4% |
| Employees | 1 | — |
Legal name
GALECTO BIOTECH ApS
CVR number
34878366
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
3. december 2012
Share capital
DKK 80.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at drive virksomhed med forskning og eksperimentel udvikling indenfor bioteknologi, og hermed forbundet virksomhed.
Address
Ole Maaløes Vej 3
Phone
+4526373726
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.582 | -14.954 | -15.029 | 865 | -1.338 | -2.113 | -2.569 | 2.423 | 4.884 | 9.407 | 12.287 | 15.257 | 5.477 |
| Staff expenses | -0 | -2.850 | -3.941 | -1.173 | -1.066 | -960 | -1.182 | -2.054 | -4.403 | -8.579 | -11.235 | -12.916 | -5.168 |
| EBITDA | -1.582 | -17.804 | -18.970 | -308 | -2.404 | -3.073 | -3.751 | 369 | 481 | 828 | 1.052 | 2.340 | 309 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -18 | -33 | -232 | -0 |
| EBIT | -1.582 | -17.804 | -18.970 | -308 | -2.404 | -3.073 | -3.751 | 369 | 481 | 810 | 1.019 | 2.109 | 309 |
| Net financials | 0 | -520 | 3.092 | -333 | 42 | -72 | -113 | 48 | -207 | 155 | -110 | -14 | 731 |
| Profit before tax | -1.582 | -15.824 | -8.098 | -641 | -2.362 | -3.144 | -3.864 | 418 | 274 | 965 | 909 | 2.095 | 1.040 |
| Tax | -0 | 1.250 | 3.890 | -137 | -519 | -403 | -205 | 94 | 60 | 200 | 90 | 1.246 | 729 |
| Net profit | -1.582 | -17.074 | -11.988 | -504 | -1.843 | -2.741 | -3.660 | 324 | 214 | 765 | 819 | 849 | 310 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 3.818 | 11.791 | 34.013 | 3.658 | 1.992 | 1.455 | 4.410 | 4.085 | 5.467 | 6.427 | 9.899 | 10.668 | 8.920 |
| Equity | -1.502 | -18.576 | -30.564 | -4.600 | -6.460 | -9.188 | -12.826 | 2.690 | 2.904 | 3.669 | 7.394 | 8.243 | 8.554 |
| Long-term debt | 0 | 27.937 | 54.507 | 7.890 | 7.866 | 10.257 | 16.975 | 776 | 750 | 1.483 | 1.235 | 67 | 42 |
| Short-term debt | 5.320 | 2.430 | 10.070 | 367 | 586 | 386 | 262 | 618 | 1.813 | 1.275 | 1.256 | 2.358 | 325 |
| Total debt | 5.320 | 30.367 | 64.577 | 8.258 | 8.452 | 10.643 | 17.237 | 1.395 | 2.563 | 2.758 | 2.491 | 2.425 | 366 |
EBITDA margin
5.6%
This company
15.8%
Market median
-65% vs market
20122024
Equity ratio
95.9%
This company
38.2%
Market median
+151% vs market
20122024
Return on equity
3.6%
This company
18.4%
Market median
-80% vs market
20122024
Net profit margin
5.7%
This company
8.1%
Market median
-30% vs market
20122024
Asset turnover
0.61×
This company
1.12×
Market median
-46% vs market
20122024
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-12-03 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
GM Management | Management | 2026 | — | — |
HT Founder | Founder | 2012 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2012 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of GALECTO BIOTECH ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Garrett Michael Winslow | Management | 0 companies |
| Hans Thalsgård Schambye | Founder | 0 companies |
| Bertil Erik Lindmark | Board of Directors | 0 companies |
| Jonathan Paul Freve | Board of Directors | 0 companies |
| Anders Hjelholt Pedersen | Board of Directors | 0 companies |